B of A Securities Maintains Neutral on United Therapeutics, Raises Price Target to $626

Benzinga Newsdesk www.benzinga.com Positive 73.1%

Neg 0% Neu 0% Pos 73.1%

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and raises the price target from $569 to $626.